Sensus Healthcare (NASDAQ:SRTS) Shares Down 2.2% - Here's What Happened

Key Points

• Sensus Healthcare's shares dropped 2.2%, trading at $3.18, with a significant decline in trading volume at 62,558 shares compared to an average of 204,478 shares.
• Wall Street analysts issued mixed ratings, with some lowering their price targets and ratings, while the average target price now stands at $8.00 despite recent cuts from various firms.
• The company reported a loss of ($0.06) EPS, missing expectations and generating revenue of $7.32 million, well below the consensus estimate of $9.30 million.

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report)'s stock price traded down 2.2% during trading on Thursday . The stock traded as low as $3.16 and last traded at $3.18. 62,558 shares changed hands during mid-day trading, a decline of 69% from the average session volume of 204,478 shares. The stock had previously closed at $3.25.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Wall Street Zen lowered Sensus Healthcare from a "hold" rating to a "sell" rating in a research note on Sunday, June 22nd. HC Wainwright reduced their price objective on Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Lake Street Capital reduced their price objective on Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Finally, Maxim Group reduced their price objective on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $8.00.

Sensus Healthcare Trading Up 1.6%

The firm has a market cap of $53.10 million, a PE ratio of -53.83 and a beta of 1.41. The stock has a 50 day simple moving average of $4.21 and a 200-day simple moving average of $4.52.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by ($0.07). Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%.The business had revenue of $7.32 million during the quarter, compared to analysts' expectations of $9.30 million. On average, equities research analysts expect that Sensus Healthcare, Inc. will post 0.32 EPS for the current year.

Institutional Investors Weigh In On Sensus Healthcare

A number of institutional investors have recently bought and sold shares of SRTS. Wealth Enhancement Advisory Services LLC bought a new position in shares of Sensus Healthcare during the 1st quarter valued at about $71,000. Millennium Management LLC boosted its holdings in shares of Sensus Healthcare by 256.6% during the 4th quarter. Millennium Management LLC now owns 85,329 shares of the company's stock valued at $590,000 after purchasing an additional 61,403 shares during the last quarter. IFP Advisors Inc boosted its holdings in shares of Sensus Healthcare by 37.2% during the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company's stock valued at $89,000 after purchasing an additional 5,100 shares during the last quarter. Pacific Ridge Capital Partners LLC bought a new position in shares of Sensus Healthcare during the 1st quarter valued at about $542,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Sensus Healthcare by 3.9% during the 1st quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company's stock valued at $672,000 after purchasing an additional 5,289 shares during the last quarter. Hedge funds and other institutional investors own 25.30% of the company's stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.